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Introduction
The introduction of erythropoiesis-stimulating agents
(ESAs) revolutionized the management of anaemia in
chronic kidney disease (CKD) patients by providing ef-
fective control of haemoglobin (Hb) levels, reducing the
need for blood transfusions and improving patient quality
of life. The use of ESAs in CKD patients is constantly
evolving as new research helps us to better understand how
to safely and effectively manage anaemia in these patients.
This supplement reviews the latest thinking on optimal Hb
control and looks to the future in the increasingly complex
landscape of ESA therapies.
Anaemia has been recognized as a risk factor for the
development of cardiovascular disease (CVD) in CKD pa-
tientsandCVDremainstheleadingcauseofhospitalization
and death in these patients. In their chapter entitled ‘Fu-
tureperspectivesontreatmentwitherythropoiesisstimulat-
ing agents’ in high-risk patients, Stefan Anker and Robert
Toto review several large-scale clinical studies designed to
address the question of whether effective management of
anaemia can improve cardiovascular (CV) outcomes. Re-
sults of the CHOIR [1] and CREATE [2] studies are dis-
cussed, along with two more recent studies, TREAT (Trial
to Reduce cardiovascular Events with Aranesp Therapy)
[3,4] and the RED-HF (Reduction of Events with Darbe-
poetin alfa in Heart Failure) trial [5], which are currently
ongoing. The latter randomized controlled studies are an-
ticipated to shed light on ESA safety at higher target Hb
levels and it is hoped that they will provide the conclusive
data still needed to establish the impact of anaemia therapy
on CVD in these patients.
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In their chapter entitled ‘Use of darbepoetin alfa in the
treatmentofanaemiaofchronickidneydisease:clinicaland
pharmacoeconomic considerations’, Fernando Carrera and
Michel Burnier provide an overview of the use of the ESA,
darbepoetin alfa (Aranesp
R ), in the treatment of anaemia
in CKD patients. Darbepoetin alfa, the first longer-acting
ESA, has been shown to offer a number of further clin-
ical and economic benefits over the shorter-acting epoet-
ins, epoetin alfa and beta. Several studies are discussed,
which demonstrate that patients either not on dialysis or
receiving dialysis can be successfully switched from epo-
etin to darbepoetin alfa at extended dosing intervals, with
no compromise in efficacy and with significant dose sav-
ings. In addition to the convenience afforded by extended
dosing intervals, pharmacoeconomic implications are also
considered. The MERCURIUS study is expected to pro-
vide further information on how improvements could be
made in all stages of ESA delivery and utilization in hos-
pitals throughout Europe. Interim data from one centre
demonstrate significant cost savings in labour and mate-
rials following a switch from epoetin to darbepoetin alfa
therapy.
Hb levels that are either too high or too low can have an
adverse effect on patient outcomes. Evidence from CHOIR
[1] and the Normal Haematocrit Trial [6] has shown that
targeting higher versus lower Hb levels (13.5 versus 11.3
g/dL and 14 versus 10 g/dL, respectively) results in an in-
crease in the risk of death and serious CV events in CKD
patients.Inlightofthis,andotheremergingevidence,treat-
ment targets have recently been re-assessed by regulatory
agencies. In the latest revision (March 2008) of the Euro-
pean product labelling (SmPC) for the ESA class of drugs,
the target treatment range was lowered to 10–12 g/dL, with
a warning not to exceed 12 g/dL [7–13]. It is clear that opti-
mal control of Hb levels is both desirable and essential, yet
maintaining patients at Hb levels that are both safe and pro-
videmaximalbenefitisacontinuingchallenge.Hblevelsin
CKDpatientshavebeenshowntomoveupanddownduring
treatment,sometimeswithquiteextremefluctuationsabove
and/or below target Hb ranges; it is important, therefore, to
understand the causes of Hb fluctuation or variability in or-
der to optimize treatment. Inflammation is believed to play
a key role in Hb variability and responsiveness to ESAs
in CKD patients. Our third paper, entitled ‘Inflammation
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and its impact on anaemia in chronic kidney disease: from
haemoglobin variability to hyporesponsiveness’, by Angel
L. M. de Francisco, Peter Stenvinkel and Sophie Vaulont
addresses the complex role of inflammation in CKD, as
evidenced by the apparent state of deranged inflammatory
markers.
It has been suggested that increased levels of pro-
inflammatorycytokinesinCKDsuppressbonemarrowery-
thropoiesis,reduceerythropoietinproductionandmodulate
iron metabolism leading to hyporesponsiveness to ESAs
and poor treatment outcomes [14,15]. The mechanisms by
which inflammatory cytokines may affect the response to
ESAs are examined. In addition, the authors discuss a num-
ber of possible strategies or interventions with which to
minimize inflammation in these patients and enhance re-
sponse to ESAs.
In addition to the increasing complexity of maintaining
patient Hb levels within narrower margins, the number of
available treatment options is also rising, not only with
respect to new ESAs, but also with the recent market entry
of epoetin biosimilars. Biosimilar molecules are defined as
‘biological products referring, but not identical, to existing
products, submitted for separate market approval following
patent expiration.’ In the final paper of the supplement,
entitled ‘Biosimilar therapeutics-what do we need to con-
sider?’, Dr Huub Schellekens highlights some important
issues surrounding biosimilars, including variability and
inconsistency in structure and purity, the impact of this
variability on patient safety and the need for further reg-
ulations (to supplement those currently in place) for their
approval and use.
Insummary,thissupplementprovidesaninformativedis-
cussion of the important issues of the day surrounding the
use of ESAs in patients with CKD. Ongoing research, dis-
cussed herein, will continue to enlighten this complicated
area, ultimately leading to safer more effective use of these
agents.
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